Literature DB >> 12072997

Serum E-cadherin concentrations and their response during laparoscopic and open cholecystectomy.

A J Karayiannakis1, K N Syrigos, A Savva, A Polychronidis, G Karatzas, C Simopoulos.   

Abstract

BACKGROUND: Elevated serum levels of the cell adhesion molecule E-cadherin have been associated with the presence of tissue injury and inflammation. We compared soluble E-cadherin response during laparoscopic and open cholecystectomy.
METHODS: The E-cadherin response to surgery was studied in 16 patients undergoing laparoscopic cholecystectomy and 12 patients undergoing open cholecystectomy. Serum E-cadherin levels were measured by an enzyme immunoassay (ELISA) preoperatively, 10 and 30 min after the commencement of surgery, and at 6 and 24 h following the operation.
RESULTS: Serum E-cadherin levels decreased progressively during laparoscopic cholecystectomy; their concentrations at 24 h after surgery were significantly lower when compared with preoperative values. In the open cholecystectomy group, serum E-cadherin levels did not differ from preoperative values at any time point. Serum E-cadherin concentrations at 24 h after surgery and the cumulative E-cadherin response were significantly higher in the open cholecystectomy group than in the laparoscopic group.
CONCLUSION: Compared with open cholecystectomy, the cumulative E-cadherin response is significantly reduced following laparoscopic cholecystectomy.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12072997     DOI: 10.1007/s00464-001-9221-4

Source DB:  PubMed          Journal:  Surg Endosc        ISSN: 0930-2794            Impact factor:   4.584


  9 in total

1.  microRNA-92a promotes lymph node metastasis of human esophageal squamous cell carcinoma via E-cadherin.

Authors:  Zhao-li Chen; Xiao-hong Zhao; Ji-wen Wang; Bao-zhong Li; Zhen Wang; Jian Sun; Feng-wei Tan; Da-peng Ding; Xiao-hui Xu; Fang Zhou; Xiao-gang Tan; Jie Hang; Su-sheng Shi; Xiao-li Feng; Jie He
Journal:  J Biol Chem       Date:  2010-12-09       Impact factor: 5.157

2.  α-Defensins and hsCRP levels in inflammatory response of standard and laparoendoscopic single-site cholecystectomy.

Authors:  Konstantinos E Tsimogiannis; Constantinos C Tellis; Alexandros D Tselepis; George Pappas-Gogos; Maria S Bakola; Evangelos C Tsimoyiannis; C E Simopoulos; Michael Pitiakoudis
Journal:  Surg Endosc       Date:  2011-10-13       Impact factor: 4.584

3.  Transient variations in the serum concentrations of cell adhesion molecules following retroperitoneal laparoscopic and open radical nephrectomy for localized renal-cell carcinoma.

Authors:  Lu Yang; Tianyong Fan; Qiang Wei; Xiaobo Cui; Siyuan Bu; Ping Han
Journal:  J Endourol       Date:  2012-08-20       Impact factor: 2.942

Review 4.  Laparoscopic versus small-incision cholecystectomy for patients with symptomatic cholecystolithiasis.

Authors:  F Keus; J A F de Jong; H G Gooszen; C J H M van Laarhoven
Journal:  Cochrane Database Syst Rev       Date:  2006-10-18

Review 5.  Soluble E-cadherin: more than a symptom of disease.

Authors:  Magdalena M Grabowska; Mark L Day
Journal:  Front Biosci (Landmark Ed)       Date:  2012-01-01

Review 6.  Small-incision versus open cholecystectomy for patients with symptomatic cholecystolithiasis.

Authors:  F Keus; J A F de Jong; H G Gooszen; C J H M van Laarhoven
Journal:  Cochrane Database Syst Rev       Date:  2006-10-18

Review 7.  Levels of soluble E-cadherin in breast, gastric, and colorectal cancers.

Authors:  Ombretta Repetto; Paolo De Paoli; Valli De Re; Vincenzo Canzonieri; Renato Cannizzaro
Journal:  Biomed Res Int       Date:  2014-09-16       Impact factor: 3.411

8.  miR-25 promotes invasion of human non-small cell lung cancer via CDH1.

Authors:  Bing Liu; Xuerong Sun
Journal:  Bioengineered       Date:  2019-12       Impact factor: 3.269

9.  MicroRNA-23a promotes neuroblastoma cell metastasis by targeting CDH1.

Authors:  Lin Cheng; Tao Yang; Yongqin Kuang; Bin Kong; Sixun Yu; Haifeng Shu; Hutian Zhou; Jianwen Gu
Journal:  Oncol Lett       Date:  2014-01-14       Impact factor: 2.967

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.